Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Electromed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Electromed's regulatory disclosures and financial reporting.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.
Electromed, Inc. (ELMD) furnished an 8-K announcing it issued a press release with financial results for the first quarter ended September 30, 2025, and updated its investor presentation. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2.
The company noted that the information, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Exchange Act, and will not be incorporated by reference into a Securities Act registration statement except as specifically referenced.
Electromed, Inc. is asking shareholders to vote at a fully virtual annual meeting on November 14, 2025. Holders of its 8,376,147 outstanding common shares as of September 17, 2025 can attend and vote online via webcast.
Shareholders will elect eight directors, ratify RSM US LLP as auditor for the year ending June 30, 2026, approve on an advisory basis executive compensation, and choose how often future say‑on‑pay votes are held, with the Board recommending annual votes. The Board recommends voting for all director nominees and for Proposals 2 and 3.
The proxy details compensation for CEO James Cunniff and CFO Bradley Nagel. In fiscal 2025, Cunniff’s total reported pay was $1,486,329, including a $519,231 salary and a $405,600 bonus, while Nagel received $756,674, including a $323,281 salary and a $202,800 bonus after a 156% payout under the 2025 bonus plan. Equity grants include time‑vested restricted stock and options. The filing also shows net income rising to $7,537,000 in 2025 and an increase in total shareholder return since 2023, and outlines board independence, committee structure, equity plans, and related‑party transaction oversight.
Andrew Summers, a director of Electromed, Inc. (ELMD), reported multiple open-market sales of company common stock on September 10 and 11, 2025. The Form 4 shows sales of 39,378, 16,203, 6,576, 404 and 3,153 shares at weighted average prices between $23.6791 and $26.6246, with sale price ranges disclosed for each lot. Some holdings are reported as indirectly owned by investment vehicles (SVP Deal Fund I LP and Summers Value Fund LP), and the filing disclaims direct beneficial ownership except to the extent of pecuniary interest. One reported sale of 3,153 shares on 09/11/2025 reduced the reporting person’s indirect holding in a specified vehicle to 0 shares according to the form. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Electromed, Inc. (ELMD) Form 144 reports a proposed sale of 65,714 shares of common stock via BTIG, LLC on the NYSE American with an aggregate market value of $1,554,136.10. The shares were acquired in the open market on 06/01/2021 and paid for in cash. The filing lists 8,349,176 shares outstanding for the class and shows no securities sold in the past three months. The proposed sale is scheduled for 09/10/2025. The filer affirms there is no undisclosed material adverse information.
Electromed, Inc. announced that its board of directors has approved a new share repurchase authorization. The company may buy back up to $10.0 million of its outstanding common stock over time through open market purchases and privately negotiated transactions. The actual amount and timing of any repurchases will depend on market conditions and other corporate considerations. Details were provided in a press release attached as an exhibit.
Electromed, Inc. (ELMD) Form 4 filed for James L. Cunniff, CEO and President. The filing reports a disposition of 1,291 common shares on 09/02/2025 at $23.95 per share to satisfy tax withholding related to vested restricted stock, reducing his holdings to 130,751 shares. On the same date he was granted 17,000 restricted shares scheduled to vest in three equal annual installments beginning September 2026, and received an employee stock option for 31,100 shares at a $23.95 exercise price exercisable in three equal annual installments beginning September 2026 and expiring 09/02/2035, leaving 31,100 options outstanding.
Electromed, Inc. (ELMD) reporting person Bradley M. Nagel, CFO, made scheduled equity transactions on 09/02/2025 that increased his overall beneficial stake. He disposed of 562 common shares to satisfy tax withholding from restricted stock vesting at an average price of $23.95, leaving him with 16,538 shares prior to additional acquisitions. He acquired 5,300 restricted shares (no cash price) that vest in three equal annual installments beginning September 2026, and received an employee stock option to buy 9,800 shares at a $23.95 exercise price expiring 09/02/2035, vesting in three equal annual installments from September 2026. After the transactions, his beneficial ownership rose to 21,838 common shares plus 9,800 option shares exercisable in the future.
Electromed, Inc. reported details in its Form 10-K that describe its business, capital structure and selected balance sheet and operating items. The company had 8,349,176 shares issued and outstanding as of June 30, 2025, down from 8,637,883 a year earlier after share repurchase programs that retired 280,017 and 220,899 shares in prior authorizations for total costs of $5,000,000 each and are now exhausted. The company maintains a $2.5 million secured line of credit with interest at prime less 1.0% (prime was 7.50% at June 30, 2025). Operating lease liabilities increased to $198,000 from $87,000 and related right-of-use assets and lease terms are disclosed. As of June 30, 2025, unrecognized compensation expense related to non-vested awards was $1,351,000 expected to be recognized over weighted-average periods near two years. The effective tax rates were 26.7% and 26.8% for fiscal 2025 and 2024. The Audit Committee and Board provide oversight of a cybersecurity risk management program co-led by senior management and third-party providers.
Electromed, Inc. disclosed that it has issued a press release reporting its financial results for the fourth quarter and fiscal year ended June 30, 2025, and furnished that press release as Exhibit 99.1 to this Form 8-K. The company also updated its investor presentation and furnished it as Exhibit 99.2, noting that the presentation may be used in meetings with investors and analysts.
The filing provides notice that the company has made results and updated presentation materials available to the market, but it does not include the financial metrics or narrative from the press release within the filing itself; interested parties must refer to the referenced exhibits for the detailed results and figures.